India Tightens Control on Cough Syrups as Government Closes a Decades-Old Regulatory Loophole
For decades, cough syrups could be sold in many of India’s smallest villages with fewer regulatory checks than in towns and cities. The exemption was created to ensure access to medicines in areas where licensed pharmacies were scarce.
That exemption is now gone.
In a significant regulatory move, the Union Ministry of Health and Family Welfare has amended the Drugs Rules, 1945, withdrawing a provision that allowed cough syrups to be sold in villages with populations below 1,000 without complying with certain retail licensing requirements. Through Gazette Notification G.S.R. 927(E), issued on 29 December 2025 and published on 30 December 2025, the government removed the word “Syrup” from a key entry in Schedule K.
The change may seem technical, but its implications are substantial.
Cough syrups will now have to be sold and dispensed through licensed pharmacies in accordance with the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945. The move reflects a broader shift towards stronger regulatory oversight, patient safety and responsible medicine use.
Why the rule matters
Schedule K of the Drugs Rules, 1945 provides exemptions from certain provisions of India’s drug regulatory framework for specified categories of medicines. One such exemption allowed cough syrups to be sold in very small villages without some retail licensing requirements.
The provision was introduced when rural healthcare infrastructure was limited and licensed pharmacies were often unavailable. Over time, however, regulators increasingly viewed the exemption as a gap in the system.
According to the Ministry of Health and Family Welfare, the amendment is intended to strengthen oversight of syrup formulations and align regulations with current public health and safety needs.
In practical terms, cough syrups will now have to move through licensed retail channels, even in India’s smallest settlements.
The medicines affected
The change affects a range of commonly used cough and cold products.
Brands such as Benadryl, Glycodin, Grilinctus, Zedex, Honitus and many others will now come under stricter retail oversight. Pharmacies will be required to follow applicable prescription and dispensing requirements.
Lozenges used for sore throat relief and cough suppression remain available over the counter.
The distinction reflects growing concern that syrup formulations carry risks not associated with simpler remedies.
A public health concern hidden in plain sight
The amendment comes amid longstanding concerns about the misuse of certain cough syrups.
Particular attention has focused on products containing codeine sulphate and dextromethorphan. Both ingredients have legitimate medical uses, but they have also been linked to recreational use among teenagers and young adults.
Codeine is an opioid medicine. At higher doses, it can produce effects similar to morphine. Some formulations may also contain ingredients with hallucinogenic properties when misused.
Evidence of the problem dates back decades. In 1997, researchers led by S.K. Mattoo at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, documented dependence among patients using codeine-containing cough syrups.
The issue continues to feature in addiction treatment settings. The National Drug Dependence Treatment Centre (NDDTC) at the All India Institute of Medical Sciences (AIIMS) identifies codeine-based cough syrups among commonly misused opioid substances.
The challenge for regulators is balancing access to legitimate medicines with safeguards against misuse.
Children, self-medication and unintended harms
Another concern involves the use of cough and cold medicines in young children.
Health authorities have repeatedly warned against using antihistamine-containing cough syrups as sedatives. Doctors have reported cases where parents administered these products to help children sleep, despite the absence of a medical need.
The Directorate General of Health Services (DGHS) and the Ministry of Health and Family Welfare have issued advisories cautioning against the use of cough and cold medicines in very young children. Many childhood coughs and colds are self-limiting, and some medicines can cause unwanted sedative effects.
The issue highlights a broader problem of unsupervised medicine use and self-medication.
By restricting sales to licensed pharmacies, regulators are seeking greater accountability in dispensing.
Access versus oversight
The amendment also revives a familiar public health question: how should governments balance access with regulation?
The original exemption addressed a genuine challenge. Many remote villages lacked pharmacies, making access to medicines difficult.
Today, regulators face growing pressure to tackle medicine misuse, irrational consumption and gaps in pharmacovigilance. At the same time, tighter controls must not create new barriers for rural populations.
The effectiveness of the amendment will depend not only on enforcement but also on the availability of licensed pharmacies and healthcare providers in underserved areas.
Manufacturers, distributors and retailers have been advised to comply fully with licensing and regulatory requirements under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945.
What this means for India’s medicine regulation
The amendment is about more than cough syrups. It reflects a broader evolution in India’s approach to medicine governance.
Modern drug regulation is no longer focused solely on product quality. It also addresses misuse, inappropriate self-medication, patient safety and responsible distribution.
A common household medicine has become the focus of a larger debate about access, oversight and public health protection.
By removing a decades-old exemption, the government has closed a regulatory loophole that many experts believed had outlived its purpose. The next challenge will be ensuring that stronger safeguards are matched by equitable access, especially in India’s most remote communities.
